# Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Source: https://onco.cc/trials/nct00272649/  
OnCo record `nct00272649` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rocapuldencel-T run by Argos Therapeutics, completed.

## Summary

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer is a phase 1/2 interventional study registered as NCT00272649 by Argos Therapeutics, with 22 participants enrolled, started 2006-01. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00272649
- Phase: 1/2
- Setting: A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma
- Sponsor: Argos Therapeutics
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT00272649: https://clinicaltrials.gov/study/NCT00272649

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct00272649.json